The National Cancer Institute seeks parties interested in collaborative research to co-develop a method to generate RNA molecules suitable for nanoparticle and biomedical applications.
The development of nanoparticles as a method of drug delivery is paving the way for precise targeted therapy making it a more attractive and effective method for treating cancer. However, the current methods of designing RNA nanoparticles are limited by three factors: 1) the cost and size limitations associated with chemical synthesis of RNA; 2) the complexity of RNA nanoparticle production; and 3) low retention time of RNA nanoparticles in the patient bloodstream due to their susceptibility to nuclease degradation.
NCI scientists have developed a method to overcome these challenges in RNA nanoparticle design. The method entails generating RNA nanoparticles having modified nucleotides and/or having increased nuclease resistance where the RNA nanoparticles are formed co-transcriptionally by T7 RNA polymerase in the presence of manganese ions. In essence, the technology results in high-yield production of chemically modified RNA nanoparticles functionalized with siRNAs that are resistant to nucleases from human blood serum
- Inexpensive and efficient method of producing chemically modified RNA nanoparticles for diagnostic or therapeutic applications.
- Reduces the cost and size limitations of solid-phase RNA synthesis.
- Simplifies production of complex RNA nanoparticles.
- Increases retention time of RNA nanoparticles.
Bruce A. Shapiro Ph.D. (NCI), Kirill A. Alfonin Ph.D., Maria L. Kireeva Ph.D., Mikhail Kashlev Ph.D.
- Afonin KA, et al. [PMID 23016824]
- Grabow WW, et al. "RNA Nanotechnology in Nanomedicine," in Nanomedicine and Drug Delivery (Recent Advances in Nanoscience and Nanotechnology), ed. M Sebastian, et al. (New Jersey: Apple Academic Press, 2012), 208-220. [Book Chapter]
- Research Material: NIH will not pursue patent prosecution for this technology